Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immune Checkpoint Inhibitors in Contemporary Management of Advanced HCC

In this segment, experts review data surrounding the use of immune checkpoint inhibitors for advanced HCC, with a discussion of how these agents fit into current treatment paradigms.
Lipika Goyal, MD
Amit G. Singal, MD, MS
Released: November 24, 2020 Expiration: No longer available for credit

This program is divided into several short segments which you can step through using the Video Chapters menu.

Related Content

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Downloadable slideset on therapies for untreated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Released: July 21, 2022

Commentary on evolving treatment paradigms in gynecologic cancers, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS
Program Director
Nicoletta Colombo, MD Shannon N. Westin, MD, MPH
Released: July 14, 2022

Experts discuss current and emerging targeted therapies and clinical considerations in the treatment of NF1 and inoperable plexiform neurofibromas, from Clinical Care Options (CCO)

person default Miriam Bornhorst, MD Carlos Romo, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 8, 2022 Expired: July 7, 2023

Video Chapters


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings